anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study aims to investigate the effects of 7 factors (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction), as measured by the Pittsburgh Sleep Quality Index, on the quality of life (QOL) in middle-aged individuals. A total of 194 middle-aged individuals aged 45 to 59 years participated in this study. The Chinese version of the medical outcomes study 36-item short-form health survey and the Pittsburgh Sleep Quality Index were used to assess the QOL and sleep quality, respectively. The relationship between sleep patterns and QOL was analyzed using fuzzy-set qualitative comparative analysis. Improvement in sleep disturbances and reduction in the use of sleeping medications are necessary conditions for enhancing QOL. Two configurations of sleep patterns positively influence QOL: the "sufficiency type" with high level of sleep duration, non-sleep disturbances, and non-daytime dysfunction as core conditions; and the "efficiency type" with high habitual sleep efficiency and non-daytime dysfunction as core conditions. Three configurations of sleep patterns negatively influence QOL: the "low-quality type" with non-high-level subjective sleep quality, sleep duration, and habitual sleep efficiency as core conditions; the "barrier type" with high level of sleep disturbances, non-high-level sleep latency, and non-high-level subjective sleep quality/sleep duration as core conditions; and the "drug-based type" with high level of use of sleeping medications and subjective sleep quality as core conditions. Using the fuzzy-set qualitative comparative analysis method, this study initially reveals that the influence of sleep patterns on QOL in middle-aged individuals is a holistic effect combining multiple elements. This deepens and enriches the understanding of the relationship between sleep patterns and QOL and expands new perspectives for more in-depth research on how to improve the QOL of middle-aged individuals through sleep interventions.
Increases in hematocrit levels, reflective of increases in red blood cell mass, may require discontinuation of AZMIRO. Check that hematocrit is not elevated prior to initiating AZMIRO. Periodically monitor hematocrit levels during treatment. If hematocrit becomes elevated, stop AZMIRO until hematocrit decreases to an acceptable concentration. If AZMIRO is restarted and again causes hematocrit to become elevated, stop AZMIRO permanently. An increase in red blood cell mass may increase the risk of thromboembolic events [ see Warnings and Precautions ( 5.4) ].
The invention provides a cosmetic base which is light and thin in touch, does not cause stickiness, and has excellent moisturizing effect, and can inhibit astringent feeling when a sunscreen cosmetic is coated immediately after the cosmetic blended with the base is used. The cosmetic base is composed of an alkylene oxide derivative represented by the formula (1). Z- [ O- (EO) a ‑{(EO) b /(PO) c }‑H] x Z is a residue obtained by removing all hydroxyl groups from a compound having 1 to 7 carbon atoms and 1 to 4 hydroxyl groups. x represents an integer of 1 to 4. EO is an oxyethylene group. PO is oxypropylene. a. b and c are average molar numbers of EO and PO added respectivelyA is more than or equal to 1 and less than or equal to 60, b is more than or equal to 1 and less than or equal to 40, c is more than or equal to 1 and less than or equal to 60, b/c is 1/10-5/1, a { a/(b + c) } is 1/10-5/1, and { (EO) b /(PO) c Addition of b moles of EO to c moles of PO in the formation of a random pattern.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of sufficiently drawing out anti-rheumatic actions, by dissolving a cyclosporin and including the solution. SOLUTION: This medicine comprises a cyclosporin as an active ingredient. The medicine together with an arbitrary additive is dissolved in water (physiological salt solution, water for injection or distilled water) and sterilized to give an agent for direct intra-articular administration. A natural type cyclosporin A or C, their phosphoric ester derivative or its salt may be cited as the cyclosporin. The content of the cyclosporin is 0.01-35 μg in the case of the natural type cyclosporin or its phosphoric ester derivative and 0.1 μg to 500 mg/mL in the case of a phosphoric ester derivative salt of the cyclosporin. Consequently effects can be exhibited without adding an additive such as a solubilizer or by directly administering a cyclosporin in an extremely small amount in a range of solubility in water to an RA joint.  Adverse effects by an additive and the whole body distribution of a cyclosporin can be avoided.
After pancreaticoduodenectomy, the post-operative complications can be surgical (pancreatic fistula, gastroparesis) but also infectious, digestive (diarrhea) and lead to malnutrition. They are responsible for prolonged post-operative hospitalizations, impaired quality of life of patients and induce a delay in the implementation of adjuvant chemotherapy, or even an impossibility to achieve it. The absence of adjuvant chemotherapy adversely affects the prognosis of patients, by increasing the rate of recurrence and decreased survival. There is therefore a real oncological benefit in finding solutions to reduce the number and severity of these complications. A change in post-operative microbiota composition has been shown to play a role in the development of post-surgical anastomotic fistulas in colorectal cancer. Despite their importance, there is very little data on the impact of microbiota on complications after pancreatic surgery. We postulate that microbiota variations could have an impact on early and late post-operative complications after pancreaticoduodenectomy. Any patient hospitalized at the Toulouse University Hospital with an indication of a pancreaticoduodenectomy will be offered to participate in this study. Microbiota analysis will be carried out on different samples: blood, stool and saliva samples will be collected during the surgery, between J5 and J10 (post-operative during hospitalization) and at 3 and 6 months after the surgery. Bile, pancreatic and intestinal mucosa samples will only be collected during the surgery. Complications will be collected throughout this study. This study will not create any additional constraints on patient management. The follow-up period will be 6 months. This follow-up period will be fixed for all patients included. The microbiota analyses will be centrally determined during the study.
Capecitabine was administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m\^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks).
COVID-19 pandemic-related traumatic stress (PRTS) symptoms are reported in various populations, but risk factors in older adults with chronic medical conditions, remain understudied. We therefore examined correlates and pre-pandemic predictors of PRTS in older adults with hypertension during COVID-19. Participants in California, aged 61-92 years (n = 95), participated in a pre-pandemic healthy aging trial and later completed a COVID-19 assessment (May to September 2020). Those experiencing ⩾1 PRTS symptom (n = 40), and those without PRTS symptoms (n = 55), were compared. The PRTS+ group had poorer mental and general health and greater impairment in instrumental activities of daily living. Pre-pandemic biomarkers of vascular inflammation did not predict increased odds of PRTS; however, greater pre-pandemic anxiety and female gender did predict PRTS during COVID-19. Our findings highlight PRTS as a threat to healthy aging in older adults with hypertension; targeted approaches are needed to mitigate this burden, particularly for females and those with pre-existing anxiety.
The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds. Diseases and disorders contemplated include, inter alia, diseases and disorders of the central nervous system, the peripheral nervous system, the gastrointestinal system, the circulatory system, skin, retina, brain, heart, and lungs.
PURPOSE:To provide a composite material which has excellent color tone such as brightness, chroma, etc., in which apparent color well agrees with interference color and which has excellent stability, safety, resistance to light and chemicals and is useful as a material for cosmetics, by coating the surface of mica with lower oxides of titanium and further TiO2. CONSTITUTION:A composite material is obtd. by coating the surface of mica of mica with lower oxides of titanium (e.g. Ti2O, TiO, Ti2O3, Ti3O5 or Ti4O7) or a titanium compd. (e.g. TiO2 or TiN) contg. The lower oxides of titanium and then further with TiO2. By the double coating of the surface of mica, a composite material can be obtd. which has greatly improved color tone such as brightness, chroma, etc., in which apparent color well agrees with interference color, and which has excellent pigment characteristics such as stability, safely, resistance to light, acids, alkalis, solvents and heat, etc. and is useful as a pigment for cosmetics, paints, daily necessities, decorations, etc. and as a colored iridescent luster material.
The incidence of inhibitors among people with severe hemophilia A has been documented as approximately 20-30% in several prospective studies. In such patients acute hemorrhages frequently occur and profoundly jeopardize health, with subsequent development of arthropathy. A common way of treating such bleeding episodes is to use bypassing agents. Among these agents the prothrombin complex concentrate FEIBA has been widely used for many years. More recently, recombinant factor VIIa (NovoSeven) has been added to the therapeutic options. While both products have been found effective in treating hemorrhages, the number of injections given for a bleeding episode has ranged widely, and it is so far unknown whether one of the products might have a better effect in certain patients.
The study was a two-step randomized (2:1) study. Patients were stratified by histology (non-squamous versus squamous), best response to first-line treatment \[complete response or partial response versus stable disease or progressive disease\] and line of treatment with prior ICI (first-line ICI when combined with platinum-based chemotherapy versus second-line ICI when administered as sequential treatment). Primary endpoint was overall survival (OS). Interim OS futility analysis was planned as per Fleming design. In April 2020 at the time of the interim analysis, a decision was taken to early stop the accrual due to COVID-19 after 219 out of 363 patients were randomized. It led to a decrease of the study power from 80% to 62%. At the time of the interim analysis, a subgroup of patients was identified from stratification factor based on a clinical and biological rationale: those who received ICI second line and having received at least 12 weeks ICI. This subgroup was defined as ICI secondary resistance. The final analysis was carried out in the subgroup of patients with ICI secondary resistance and in all patients (ICI primary and secondary resistance).
The invention relates to a topiramate medicine composition. In the composition, pregelatinized starch is added, the stability of the active components of topiramate is increased, and therefore the quality and security of the composition can be ensured. In the composition, the pregelatinized starch also plays a role of a dry binder, the hardness and the friability of the composition are ensured, the amounts of auxiliary materials are decreased, and the cost is saved. The invention also relates to a preparation method for the topiramate medicine composition. The preparation method comprises a dry granulation technology. The preparation method has simple technology. The finished products after granulation are epigranular, which is convenient for storage and transportation. The topiramate medicine composition is suitable for industrialized production.
Patients will receive unilateral accelerated theta-burst stimulation to the left side for 5 consecutive days, with a total of 10 hours a day. treatment will be 10min with 50min of breaks in between the 10 sessions. There will be a right DLPFC sham component to this treatment arm for all treatment sessions.
It is useful to consider time in critical illness from two perspectives. The first of these begins logically with onset of the pathology. With the exception of conditions such as myocardial infarction or trauma where this moment is marked by a classic symptom or an external event, then defining time zero is difficult. For this reason, an organisational frame of reference, such as hospital admission or time of referral to specialist team, is more commonly used. Delay following this organisational time is important because it is often a modifiable factor with regard to the delivery of health care. However, pathophysiological timing remains relevant because if the disease process is dynamic (and this is part of the hypothesis of this study) then it determines the phenotype of disease at any particular moment.

This project proposes to measure delay to admission to Intensive Care (ICU) using both organisational and pathophysiological timing. Delays in the United Kingdom NHS are widely reported {McQuillan:1998p127, Hillman:2001p90} possibly because there are fewer ICU beds than in many other developed health care systems.{Wunsch:2008p121} We intend to measure the chronological time between the moment when a patient is 'referred and assessed as requiring Critical Care', and their actual time of admission. We will determine how often delays occur, and whether they affect outcome. Requirements for critical care are not, however, absolute. Importantly, the assessment of a prospective patient is not made in isolation. If ICU beds are already fully occupied, then decision makers must organise a transfer to another unit (with risks to the patient), organise a premature discharge of another patient, or defer admission. We will also therefore consider such deferments alongside delays, and their impact on survival.

In addition, the project will consider pathophysiological timing. This is of particular importance in sepsis where current biological models suggest that there is a phased response to infection.{Riedemann:2003p82} In this case, it is possible that patients are admitted to critical care at different phases of disease; moreover, these phases may be clinically relevant and affect response to treatment. pathophysiological delay will be estimated using the concept of illness trajectories (which also may have a biological correlate){Osuchowski:2006p2107}. This means that a patient who is slowly deteriorating is likely to have been ill for longer. In other words, their pathophysiological time zero will be earlier than another patient who is is rapidly deteriorating. This illness trajectory will be estimated by measuring the change in severity of illness between ward assessment and ICU admission. The effect of these illness trajectories, and therefore of the pathophysiological timing of ICU admission, will be evaluated with particular attention to severe sepsis.
In controlled clinical trials, 26% (266/1,008) of adult subjects treated with 600 mg EFV experienced new-onset skin rash compared with 17% (111/635) of those treated in control groups. Rash associated with blistering, moist desquamation, or ulceration occurred in 0.9% (9/1,008) of subjects treated with EFV. The incidence of Grade 4 rash (e.g., erythema multiforme, Stevens-Johnson syndrome) in adult subjects treated with EFV in all trials and expanded access was 0.1%. Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 2 weeks of initiating therapy with EFV (median time to onset of rash in adults was 11 days) and, in most subjects continuing therapy with EFV, rash resolves within 1 month (median duration, 16 days). The discontinuation rate for rash in adult clinical trials was 1.7% (17/1,008). Efavirenz, emtricitabine and tenofovir disoproxil fumarate can be reinitiated in patients interrupting therapy because of rash. Efavirenz, emtricitabine and tenofovir disoproxil fumarate should be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement, or fever. Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash. For patients who have had a life-threatening cutaneous reaction (e.g., Stevens-Johnson syndrome), alternative therapy should be considered [see Contraindications (4)].

  


Experience with EFV in subjects who discontinued other antiretroviral agents of the NNRTI class is limited. Nineteen subjects who discontinued nevirapine because of rash have been treated with EFV. Nine of these subjects developed mild-to-moderate rash while receiving therapy with EFV, and two of these subjects discontinued because of rash.

  


Rash was reported in 59 of 182 pediatric subjects (32%) treated with EFV [see Adverse Reactions (6.1)]. Two pediatric subjects experienced Grade 3 rash (confluent rash with fever, generalized rash), and four subjects had Grade 4 rash (erythema multiforme). The median time to onset of rash in pediatric subjects was 28 days (range 3 to 1,642 days). Prophylaxis with appropriate antihistamines before initiating therapy with efavirenz, emtricitabine and tenofovir disoproxil fumarate in pediatric patients should be considered.
Participants randomized to the MC group will complete a 60 minute computer intervention focused on motivation to initiate and engage in treatment. The program will be self-guided, interactive, and to the extent possible, will mirror the features of MI session. The MC program will have two main components: a motivation component and a planning component.
<P>PROBLEM TO BE SOLVED: To produce a conventionally unknown heterooligosaccharide by utilizing a sugar-transfer reaction of an α-amylase (EC 3,2,1,1) which is a hydrolytic enzyme.  <P>SOLUTION: The method for producing an oligosaccharide composition comprises reacting the α-amylase with a mixed sugar liquid containing a starch and/or a hydrolyzed product of the starch, and oligosaccharides which are an enzymically hydrolyzed product of a sugar alcohol, a monosaccharide except glucose, or the starch, and which contain the oligosaccharides except the oligosaccharides having the glucose bonded thereto by α-1,4 bond and/or α-1,6 bond. The method for producing an oligosaccharide composition involves reacting a β-amylase or a glucoamylase with the oligosaccharide composition produced by the method. The oligosaccharide compositions are produced by the methods. The heterooligosaccharide is obtained from the oligosaccharide compositions. The sugar composition contains the oligosaccharide composition or the heterooligosaccharide. The food, beverage, seasoning, taste quality-improver, composition for dental health, cosmetic, fodder or composition for shampooing contains the oligosaccharide composition, the heterooligosaccharide or the sugar composition.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Recent advancements highlight the intricate interplay between the extracellular matrix (ECM) and immune responses, notably in respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). The ECM, a dynamic structural framework within tissues, orches-trates a plethora of cellular processes, including immune cell behavior and tissue repair mecha-nisms. WNT1-inducible-signaling pathway protein 1 (WISP1), a key ECM regulator, controls immune cell behavior, cytokine production, and tissue repair by modulating integrins, PI3K, Akt, β-catenin, and mTOR signaling pathways. WISP1 also induces macrophage migration inhibitory factor (MIF) expression via Src kinases and epidermal growth factor receptor (EGFR) activation. MIF, through its wide range of activities, enhances inflammation and tissue restructuring. Rec-ognized for its versatile roles in regulating the immune system, MIF interacts with multiple immune components, such as the NLRP3 inflammasome, thereby sustaining inflammatory pro-cesses. The WISP1-MIF axis potentially unveils complex molecular mechanisms governing im-mune responses and inflammation. Understanding the intricate roles of WISP1 and MIF in the pathogenesis of chronic respiratory diseases such as asthma and COPD could lead to the identi-fication of novel targets for therapeutic intervention to alleviate disease severity and enhance patient outcomes.
Participants received a single oral dose of test treatment of tepotinib TF3 (5 \* 100 mg) in treatment period 1 followed by a single oral dose of reference treatment of tepotinib TF3 (2 \* 250 mg) in treatment period 2. The treatment periods were separated by 21 day washout period.
Pain factors are labeled with targeted agents or markers delivered into the body. The labeled pain factors are imaged with appropriate imaging tools in a manner allowing selective identification and localization of areas of pain source or transmission. The labeled pain factors allow spatial differentiation in the imaging sufficient to specify the location of the pain so as to drive therapeutic decisions and techniques in order to treat the pain. Pain factors labeled and imaged in this manner may include one or more of nerve factors, blood vessel factors, cellular factors, and inflammation factors. Labeled markers may include for example radioactive materials (e.g. tritiated or iodinated molecules) or other materials such as metal (e.g. gold) nanoparticles. Intermediary binding materials may be used, such as for example bi-specific antibodies. Therapeutic components of the system and method include for example localized energy delivery or ablation treatments, or local drug or other chemical delivery. Locations containing pain factor selectively bound by targeted agents are selectively treated with directed energy into a region containing the targeted agent bound to the pain factor.
Participants with body weight ≥30 kg (Cohort A) were randomly assigned in a factorial design during the RCT to (1) HCL plus intensive diabetes management or usual care with no HCL and (2) verapamil or placebo. No interventions were administered during the observational extension.
Study participation will involve 9 study visits over a total of 12 weeks. This includes 5 sessions of Case Manager implemented PST over a period of 8 weeks (week 1, 3, 5, 7, and 9) and 4 assessment visits (baseline, week 4, week 8, and week 12).